Zydus Lifesciences has entered into a strategic partnership with oncology firm Guardant Health to jointly promote a range of liquid and tissue biopsy tests across India and Nepal. The co-marketing agreement includes the promotion of Guardant360 portfolio tests, such as Guardant360, Guardant360 TissueNext, and Guardant360 Response. This collaboration aims to advance precision medicine, providing oncologists with essential tools for informed treatment decisions and improving outcomes for patients with advanced cancer. The partnership reflects a shared commitment to addressing unmet needs in cancer treatment through genomic testing and targeted therapies.